Clinical trials: Neoplasms, Oral
Thrombocytopaenia
Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide
The study will evaluate the safety and tolerability, optimal biologic dose, and pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet count and are receiving ADRIAMYCIN and ifosfamide (AI)…
- Trial name
- NCT00358540
- Testing
- eltrombopag
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy.
- Trial name
- NCT00445068
- Testing
- LBH589
- Where
- 29 sites in United States, Germany
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis
Ulcerative colitis is characterized by abnormal activation of, and damage to, the colon epithelium, which is considered to be a central pathogenic mechanism.
- Trial name
- NCT00727324
- Testing
- bovine intestinal alkaline phosphatase (BIAP)
- Where
- 11 sites in Czechia, Italy
- Volunteers
- 22 people
- Sponsor
- AM-Pharma
Cancer
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
This is a Phase I, open-label, non-randomized, sequential, two-period, repeat-dose study to evaluate the effect of trametinib 2 milligram (mg) once daily on the repeat-dose pharmacokinetic (PK) of an oral contraceptive (OC)…
- Trial name
- NCT02292732
- Testing
- Trametinib 0.5 mg, Trametinib 2 mg, ORTHO-NOVUM® tablet 1/35
- Sponsor
- GlaxoSmithKline
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity…
- Trial name
- LAM-002A/NHL (NCT02594384)
- Testing
- LAM-002A, Rituximab, Atezolizumab
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- IRulya Therapeutics Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Solid Tumors
A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors
This is a Japanese multicenter, open-label, Phase 1 study to evaluate safety and efficacy of MSC2156119J in subjects with malignant solid tumor which is refractory to standard therapy or to which no effective standard therapy is…
- Trial name
- NCT01832506
- Testing
- MSC2156119J
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor
Study Of ATRN-119 In Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of ATRN-119 through the performance of a Phase 1/2a, open-label, safety, PK, and preliminary efficacy study of oral ATRN-119 in patients with advanced solid…
- Trial name
- ABOYA-119 (NCT04905914)
- Testing
- ATRN-119
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Aprea Therapeutics
Bone Marrow Diseases, Myelodysplastic Syndromes
SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.
The purpose of this study is to determine the safety and effectiveness of oral SCIO-469 in patients with myelodysplastic syndromes.
- Conditions
- Bone Marrow Diseases, Myelodysplastic Syndromes, Hematologic Diseases, Bone Marrow Neoplasms
- Trial name
- NCT00113893
- Testing
- SCIO-469
- Volunteers
- 62 people
- Sponsor
- Scios, Inc.
Hepatic Impairment, Advanced Malignant Solid Tumor
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat. The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe…
- Trial name
- NCT04241835
- Testing
- Tazemetostat
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 18 people
- Sponsor
- Epizyme, Inc.
Oral Mucositis, Stomatitis
Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine
The purpose of this study is to compare the incidence of stomatitis when treating with amifostine before radiation treatment.
- Trial name
- NCT01288625
- Testing
- Amifostine
- Sponsor
- Sun Pharmaceutical Industries Limited
Advanced Solid Tumors (Excluding Breast Cancer)
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the cardiac safety of TAS-102 in patients with advanced solid tumors.
- Trial name
- NCT01867879
- Testing
- TAS-102
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Taiho Oncology, Inc.
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and…
- Trial name
- NCT03260179
- Testing
- AL3810
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Mastocytosis
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
This is a 12 weeks study aimed at assessing the safety and efficacy of 2 doses of AB1010 in patients suffering from indolent systemic mastocytosis with handicap.
- Trial name
- NCT00831974
- Testing
- masitinib (AB1010)
- Volunteers
- 23 people
- Sponsor
- AB Science
Pain, Analgesics, Opioid
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
The purpose of this study was to demonstrate the clinical equivalence of hydromorphone and morphine (immediate-release [IR] and sustained-release [SR] formulations) using the "worst pain in the past 24 hours" item of the Brief…
- Trial name
- NCT00410540
- Testing
- OROS hydromorphone HCL ; Morphine sulfate
- Volunteers
- 202 people
- Sponsor
- Alza Corporation, DE, USA
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- Trial name
- NCT00830518
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
This is an open-label, single centre, Phase I study to determine the brain exposure of [11C]osimertinib in patients with EGFRm NSCLC with brain metastases.
- Trial name
- ODIN-BM (NCT03463525)
- Testing
- Osimertinib, [11C]osimertinib
- Where
- Sweden
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Neoplasms, Breast
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients.
- Trial name
- NCT00258050
- Testing
- Midazolam, Lapatinib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Neoplasms
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
To evaluate the safety and tolerability of oral SKI-606 (bosutinib) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population.
- Trial name
- NCT00195260
- Testing
- bosutinib
- Where
- 19 sites in United States
- Volunteers
- 151 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.